PROCEPT BioRobotics（PRCT *）株式概要PROCEPT BioRobotics Corporationは手術用ロボットの会社で、米国および国際的に泌尿器科における変革的ソリューションの開発に注力している。 詳細PRCT * ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長1/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間17.7%増加すると予測されています リスク分析株式の流動性は非常に低い 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るPRCT * Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,370 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,370 investors already sharing narrativesYour Fair ValueMex$Current PriceMex$357.003.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-103m727m2016201920222025202620282031Revenue US$727.3mEarnings US$96.2mAdvancedSet Fair ValueView all narrativesPROCEPT BioRobotics Corporation 競合他社Médica Sur. deSymbol: BMV:MEDICA BMarket cap: Mex$6.5bZylox-Tonbridge Medical TechnologySymbol: SEHK:2190Market cap: HK$6.5bStar Sports MedicineSymbol: SEHK:1609Market cap: HK$7.3bSino Medical Sciences TechnologySymbol: SHSE:688108Market cap: CN¥6.4b価格と性能株価の高値、安値、推移の概要PROCEPT BioRobotics過去の株価現在の株価US$357.0052週高値US$653.9252週安値US$356.00ベータ0.871ヶ月の変化-25.47%3ヶ月変化-17.27%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-68.66%最新ニュースお知らせ • Jul 15PROCEPT BioRobotics Corporation to Report Q2, 2026 Results on Aug 04, 2026PROCEPT BioRobotics Corporation announced that they will report Q2, 2026 results After-Market on Aug 04, 2026お知らせ • May 29PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE ApprovalPROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact.お知らせ • Apr 23PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United Statesお知らせ • Apr 10PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026お知らせ • Mar 23PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology GuidelinesPROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects.お知らせ • Mar 13Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation TherapyPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects.最新情報をもっと見るRecent updatesお知らせ • Jul 15PROCEPT BioRobotics Corporation to Report Q2, 2026 Results on Aug 04, 2026PROCEPT BioRobotics Corporation announced that they will report Q2, 2026 results After-Market on Aug 04, 2026お知らせ • May 29PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE ApprovalPROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact.お知らせ • Apr 23PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United Statesお知らせ • Apr 10PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026お知らせ • Mar 23PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology GuidelinesPROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects.お知らせ • Mar 13Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation TherapyPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects.お知らせ • Mar 06Procept Biorobotics Corporation Appoints Daniel Puckett Board and Audit Committee Member, Effective March 5, 2026On March 5, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from eight members to nine members, (ii) appointed Mr. Daniel Puckett as a new member of the Board to fill the resulting vacancy, and (iii) appointed Mr. Puckett as a member of the Audit Committee of the Board, with such appointment effective immediately. Mr. Puckett was classified as a Class III director, and his initial term will expire at the Company’s 2027 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Puckett is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market, and, accordingly, determined he is qualified to serve on the Audit Committee of the Board. Mr. Puckett previously served as Chief Financial Officer of Shockwave Medical Inc., a leading medical device company that develops treatments for cardiovascular disease, from April 2016 until his retirement in February 2024. Prior to Shockwave Medical, he served as Chief Financial Officer of Counsyl Inc., from June 2015 to April 2016 and as Chief Financial Officer of Ariosa Diagnostics Inc. from 2011 to June 2015. Earlier in his career, Mr. Puckett held senior finance and operations roles at Forest Laboratories Inc. and its subsidiary Cerexa Inc., as well as at Affymetrix Inc. and AOL Inc. He received an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University.お知らせ • Feb 26+ 1 more updateProcept Biorobotics Corporation Provides Financial Guidance for the Year 2027PROCEPT BioRobotics Corporation provided financial guidance for the year 2027. The company expects 2027 annual revenue growth of 25% to 30% and 2027 gross margin of 68% - to 70%.お知らせ • Jan 27PROCEPT BioRobotics Corporation to Report Q4, 2025 Results on Feb 24, 2026PROCEPT BioRobotics Corporation announced that they will report Q4, 2025 results at 4:00 PM, Central European Standard Time on Feb 24, 2026お知らせ • Nov 05Procept Biorobotics Corporation Reiterates Earnings Guidance for 2025 and Provides Revenue Guidance for 2026PROCEPT BioRobotics Corporation reiterated earnings guidance for 2025 and Provides revenue guidance for 2026. The Company reiterates revenue for the full year 2025 to be approximately $325.5 million, which represents 45% growth over the Company’s prior year revenue. The Company projects revenue for the full year 2026 to be in the range of $410 to $430 million, which represents growth of 26% to 32% over the Company’s 2025 revenue guidance range.お知らせ • Oct 16PROCEPT BioRobotics Corporation to Report Q3, 2025 Results on Nov 04, 2025PROCEPT BioRobotics Corporation announced that they will report Q3, 2025 results After-Market on Nov 04, 2025お知らせ • Aug 07PROCEPT BioRobotics Corporation Increases Earnings Guidance for the Full Year 2025PROCEPT BioRobotics Corporation increased earnings guidance for the full year 2025. The company projected revenue for the full year 2025 revenue to be approximately $325.5 million, which represents 45% growth over the company’s prior year revenue. This compares to previous revenue guidance of $323.0 million. The company expects net loss for the full year 2025 to be $83,500,000.お知らせ • Jul 25+ 1 more updatePROCEPT BioRobotics Corporation Announces Chief Executive Officer ChangesPROCEPT BioRobotics Corporation announced on July 23, 2025, the company appointed Larry L. Wood, 59, as Chief Executive Officer of the Company, effective as of September 2, 2025 (the Effective Date). As of the close of business on September 1, 2025, Dr. Reza Zadno will step down from his roles as the Company’s Chief Executive Officer. Dr. Zadno will transition to a consulting role with the Company. Dr. Zadno’s departure is not the result of any disagreement between him and the Company on any matter relating to the Company’s operations, policies or practices. Since 2020, Dr. Zadno has led the Company through significant growth and commercial expansion, including adoption and utilization of Aquablation therapy for the treatment of BPH, the Company’s successful 2021 public offering, and the start of clinical trials for the treatment of prostate cancer. Mr. Wood’s appointment follows an extensive and coordinated succession search process overseen by the Board with the assistance of a leading external search firm. During this process, the Board evaluated numerous high-quality candidates. Mr. Wood has served as a member of the Company’s Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School. On July 23, 2025, the Company and Mr. Wood entered into an employment agreement in respect of his service as Chief Executive Officer. On July 23, 2025, the Company also entered into a transition consulting and retirement agreement with Dr. Zadno (the Consulting Agreement) whereby Dr. Zadno will serve as an advisor to the Company for a period of up to eighteen (18) months (the Consulting Period).お知らせ • Jul 23PROCEPT BioRobotics Corporation Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation TherapyPROCEPT BioRobotics Corporation announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation®? therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation®? therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evaluate and compare the safety and efficacy of Aquablation therapy and radical prostatectomy For men with Grade Group 1 to 3 localized prostate cancer. Aquablation therapy is an image-guided, minimally invasive surgery that aims to resect (remove) diagnosed cancer and most of the prostate using a robotically-controlled waterjet. Radical prostatectomy is a traditional surgery that removes the entire prostate along with some surrounding tissue. A surgical robot is often used to perform the radical prostatectomy surgery.お知らせ • Jul 22PROCEPT BioRobotics Corporation to Report Q2, 2025 Results on Aug 06, 2025PROCEPT BioRobotics Corporation announced that they will report Q2, 2025 results at 4:00 PM, Central European Standard Time on Aug 06, 2025お知らせ • Apr 25PROCEPT BioRobotics Corporation Increases Revenue Guidance for the Year 2025PROCEPT BioRobotics Corporation increased revenue guidance for the year 2025. The Company projects revenue for the full year 2025 to be $323.0 million, which represents 44% growth over the Company’s prior year revenue. This compares to previous revenue guidance of $320.0 million.お知らせ • Apr 12PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025.お知らせ • Mar 25PROCEPT BioRobotics Corporation Announces WATER III Randomized-Controlled Trial ResultsPROCEPT BioRobotics® Corporation announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prostate sizes 80-180mL. The study treated 186 men between December 2020 and September 2024 and reported three-month primary safety and efficacy endpoints and will subsequently follow patients to five years. The three-month results demonstrated that Aquablation therapy delivered substantially similar symptom relief while showing significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%. These findings demonstrate that modern Aquablation therapy techniques are both safe and highly reproducible in managing bleeding risk. These results add to Aquablation therapy’s robust clinical foundation, which include the randomized WATER study (Aquablation therapy vs. TURP in 30-80 mL prostates) with five-year results, WATER II (Aquablation therapy in large prostates 80-150 mL) with five-year results, coupled with over 150 peer-reviewed publications. The growing body of clinical evidence, including multiple randomized clinical studies, demonstrate Aquablation therapy is a globally, reproducible procedure with the potential to become the BPH standard of care for all prostate sizes.株主還元PRCT *MX Medical EquipmentMX 市場7D0%0%0%1Yn/a0%0%株主還元を見る業界別リターン: PRCT *がMX Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PRCT * MX市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PRCT *'s price volatile compared to industry and market?PRCT * volatilityPRCT * Average Weekly Movementn/aMedical Equipment Industry Average Movement0%Market Average Movement0%10% most volatile stocks in MX Market0%10% least volatile stocks in MX Market0%安定した株価: PRCT *の株価は、 MX市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のPRCT *のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007888Larry Woodwww.procept-biorobotics.comPROCEPT BioRobotics Corporationは、手術用ロボット企業であり、米国内外の泌尿器科における変革的ソリューションの開発に注力している。同社は、前立腺肥大症の治療を中心とした低侵襲泌尿器科手術に使用する画像誘導型手術ロボットシステムであるアクアビーム・ロボティック・システムを開発、製造、販売している。また、前立腺肥大症による下部尿路症状に悩む男性を治療するためのAquablation療法画像誘導ロボット療法を提供するHYDROS Robotic Systemも提供している。PROCEPT BioRobotics Corporationは2007年に設立され、カリフォルニア州サンノゼに本社を置いている。もっと見るPROCEPT BioRobotics Corporation 基礎のまとめPROCEPT BioRobotics の収益と売上を時価総額と比較するとどうか。PRCT * 基礎統計学時価総額Mex$18.34b収益（TTM）-Mex$1.78b売上高(TTM)Mex$5.60b3.3xP/Sレシオ-10.3xPER（株価収益率PRCT * は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PRCT * 損益計算書（TTM）収益US$322.02m売上原価US$116.01m売上総利益US$206.01mその他の費用US$308.49m収益-US$102.47m直近の収益報告Mar 31, 2026次回決算日Aug 04, 2026一株当たり利益（EPS）-1.80グロス・マージン63.97%純利益率-31.82%有利子負債／自己資本比率14.9%PRCT * の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 15:56終値2026/07/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PROCEPT BioRobotics Corporation 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関David RescottBairdStephanie PiazzolaBofA Global ResearchStephanie ElghaziBofA Global Research19 その他のアナリストを表示
お知らせ • Jul 15PROCEPT BioRobotics Corporation to Report Q2, 2026 Results on Aug 04, 2026PROCEPT BioRobotics Corporation announced that they will report Q2, 2026 results After-Market on Aug 04, 2026
お知らせ • May 29PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE ApprovalPROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact.
お知らせ • Apr 23PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United States
お知らせ • Apr 10PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026
お知らせ • Mar 23PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology GuidelinesPROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects.
お知らせ • Mar 13Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation TherapyPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects.
お知らせ • Jul 15PROCEPT BioRobotics Corporation to Report Q2, 2026 Results on Aug 04, 2026PROCEPT BioRobotics Corporation announced that they will report Q2, 2026 results After-Market on Aug 04, 2026
お知らせ • May 29PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE ApprovalPROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact.
お知らせ • Apr 23PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United States
お知らせ • Apr 10PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026
お知らせ • Mar 23PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology GuidelinesPROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects.
お知らせ • Mar 13Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation TherapyPROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects.
お知らせ • Mar 06Procept Biorobotics Corporation Appoints Daniel Puckett Board and Audit Committee Member, Effective March 5, 2026On March 5, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from eight members to nine members, (ii) appointed Mr. Daniel Puckett as a new member of the Board to fill the resulting vacancy, and (iii) appointed Mr. Puckett as a member of the Audit Committee of the Board, with such appointment effective immediately. Mr. Puckett was classified as a Class III director, and his initial term will expire at the Company’s 2027 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Puckett is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market, and, accordingly, determined he is qualified to serve on the Audit Committee of the Board. Mr. Puckett previously served as Chief Financial Officer of Shockwave Medical Inc., a leading medical device company that develops treatments for cardiovascular disease, from April 2016 until his retirement in February 2024. Prior to Shockwave Medical, he served as Chief Financial Officer of Counsyl Inc., from June 2015 to April 2016 and as Chief Financial Officer of Ariosa Diagnostics Inc. from 2011 to June 2015. Earlier in his career, Mr. Puckett held senior finance and operations roles at Forest Laboratories Inc. and its subsidiary Cerexa Inc., as well as at Affymetrix Inc. and AOL Inc. He received an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University.
お知らせ • Feb 26+ 1 more updateProcept Biorobotics Corporation Provides Financial Guidance for the Year 2027PROCEPT BioRobotics Corporation provided financial guidance for the year 2027. The company expects 2027 annual revenue growth of 25% to 30% and 2027 gross margin of 68% - to 70%.
お知らせ • Jan 27PROCEPT BioRobotics Corporation to Report Q4, 2025 Results on Feb 24, 2026PROCEPT BioRobotics Corporation announced that they will report Q4, 2025 results at 4:00 PM, Central European Standard Time on Feb 24, 2026
お知らせ • Nov 05Procept Biorobotics Corporation Reiterates Earnings Guidance for 2025 and Provides Revenue Guidance for 2026PROCEPT BioRobotics Corporation reiterated earnings guidance for 2025 and Provides revenue guidance for 2026. The Company reiterates revenue for the full year 2025 to be approximately $325.5 million, which represents 45% growth over the Company’s prior year revenue. The Company projects revenue for the full year 2026 to be in the range of $410 to $430 million, which represents growth of 26% to 32% over the Company’s 2025 revenue guidance range.
お知らせ • Oct 16PROCEPT BioRobotics Corporation to Report Q3, 2025 Results on Nov 04, 2025PROCEPT BioRobotics Corporation announced that they will report Q3, 2025 results After-Market on Nov 04, 2025
お知らせ • Aug 07PROCEPT BioRobotics Corporation Increases Earnings Guidance for the Full Year 2025PROCEPT BioRobotics Corporation increased earnings guidance for the full year 2025. The company projected revenue for the full year 2025 revenue to be approximately $325.5 million, which represents 45% growth over the company’s prior year revenue. This compares to previous revenue guidance of $323.0 million. The company expects net loss for the full year 2025 to be $83,500,000.
お知らせ • Jul 25+ 1 more updatePROCEPT BioRobotics Corporation Announces Chief Executive Officer ChangesPROCEPT BioRobotics Corporation announced on July 23, 2025, the company appointed Larry L. Wood, 59, as Chief Executive Officer of the Company, effective as of September 2, 2025 (the Effective Date). As of the close of business on September 1, 2025, Dr. Reza Zadno will step down from his roles as the Company’s Chief Executive Officer. Dr. Zadno will transition to a consulting role with the Company. Dr. Zadno’s departure is not the result of any disagreement between him and the Company on any matter relating to the Company’s operations, policies or practices. Since 2020, Dr. Zadno has led the Company through significant growth and commercial expansion, including adoption and utilization of Aquablation therapy for the treatment of BPH, the Company’s successful 2021 public offering, and the start of clinical trials for the treatment of prostate cancer. Mr. Wood’s appointment follows an extensive and coordinated succession search process overseen by the Board with the assistance of a leading external search firm. During this process, the Board evaluated numerous high-quality candidates. Mr. Wood has served as a member of the Company’s Board since April 2024. Since February 2007, Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement, and since 2023, as Group President for Surgical Structural Heart, at Edwards Lifesciences Corporation. Mr. Wood has more than 40 years of experience in the medical technology industry at both Edwards Lifesciences Corporation and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood received an M.B.A. from Pepperdine Graziadio Business School. On July 23, 2025, the Company and Mr. Wood entered into an employment agreement in respect of his service as Chief Executive Officer. On July 23, 2025, the Company also entered into a transition consulting and retirement agreement with Dr. Zadno (the Consulting Agreement) whereby Dr. Zadno will serve as an advisor to the Company for a period of up to eighteen (18) months (the Consulting Period).
お知らせ • Jul 23PROCEPT BioRobotics Corporation Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation TherapyPROCEPT BioRobotics Corporation announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation®? therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation®? therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evaluate and compare the safety and efficacy of Aquablation therapy and radical prostatectomy For men with Grade Group 1 to 3 localized prostate cancer. Aquablation therapy is an image-guided, minimally invasive surgery that aims to resect (remove) diagnosed cancer and most of the prostate using a robotically-controlled waterjet. Radical prostatectomy is a traditional surgery that removes the entire prostate along with some surrounding tissue. A surgical robot is often used to perform the radical prostatectomy surgery.
お知らせ • Jul 22PROCEPT BioRobotics Corporation to Report Q2, 2025 Results on Aug 06, 2025PROCEPT BioRobotics Corporation announced that they will report Q2, 2025 results at 4:00 PM, Central European Standard Time on Aug 06, 2025
お知らせ • Apr 25PROCEPT BioRobotics Corporation Increases Revenue Guidance for the Year 2025PROCEPT BioRobotics Corporation increased revenue guidance for the year 2025. The Company projects revenue for the full year 2025 to be $323.0 million, which represents 44% growth over the Company’s prior year revenue. This compares to previous revenue guidance of $320.0 million.
お知らせ • Apr 12PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025.
お知らせ • Mar 25PROCEPT BioRobotics Corporation Announces WATER III Randomized-Controlled Trial ResultsPROCEPT BioRobotics® Corporation announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prostate sizes 80-180mL. The study treated 186 men between December 2020 and September 2024 and reported three-month primary safety and efficacy endpoints and will subsequently follow patients to five years. The three-month results demonstrated that Aquablation therapy delivered substantially similar symptom relief while showing significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%. These findings demonstrate that modern Aquablation therapy techniques are both safe and highly reproducible in managing bleeding risk. These results add to Aquablation therapy’s robust clinical foundation, which include the randomized WATER study (Aquablation therapy vs. TURP in 30-80 mL prostates) with five-year results, WATER II (Aquablation therapy in large prostates 80-150 mL) with five-year results, coupled with over 150 peer-reviewed publications. The growing body of clinical evidence, including multiple randomized clinical studies, demonstrate Aquablation therapy is a globally, reproducible procedure with the potential to become the BPH standard of care for all prostate sizes.
